243 related articles for article (PubMed ID: 35641240)
21. Structural mechanism of CCM3 heterodimerization with GCKIII kinases.
Zhang M; Dong L; Shi Z; Jiao S; Zhang Z; Zhang W; Liu G; Chen C; Feng M; Hao Q; Wang W; Yin M; Zhao Y; Zhang L; Zhou Z
Structure; 2013 Apr; 21(4):680-8. PubMed ID: 23541896
[TBL] [Abstract][Full Text] [Related]
22. CCM3/PDCD10 heterodimerizes with germinal center kinase III (GCKIII) proteins using a mechanism analogous to CCM3 homodimerization.
Ceccarelli DF; Laister RC; Mulligan VK; Kean MJ; Goudreault M; Scott IC; Derry WB; Chakrabartty A; Gingras AC; Sicheri F
J Biol Chem; 2011 Jul; 286(28):25056-64. PubMed ID: 21561863
[TBL] [Abstract][Full Text] [Related]
23. Depletion of protein kinase STK25 ameliorates renal lipotoxicity and protects against diabetic kidney disease.
Cansby E; Caputo M; Gao L; Kulkarni NM; Nerstedt A; Ståhlman M; Borén J; Porosk R; Soomets U; Pedrelli M; Parini P; Marschall HU; Nyström J; Howell BW; Mahlapuu M
JCI Insight; 2020 Dec; 5(24):. PubMed ID: 33170807
[TBL] [Abstract][Full Text] [Related]
24. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
[TBL] [Abstract][Full Text] [Related]
25. Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice.
Nuñez-Durán E; Aghajan M; Amrutkar M; Sütt S; Cansby E; Booten SL; Watt A; Ståhlman M; Stefan N; Häring HU; Staiger H; Borén J; Marschall HU; Mahlapuu M
Hepatol Commun; 2018 Jan; 2(1):69-83. PubMed ID: 29404514
[TBL] [Abstract][Full Text] [Related]
26. Lipotoxicity-induced STING1 activation stimulates MTORC1 and restricts hepatic lipophagy.
Liu K; Qiu D; Liang X; Huang Y; Wang Y; Jia X; Li K; Zhao J; Du C; Qiu X; Cui J; Xiao Z; Qin Y; Zhang Q
Autophagy; 2022 Apr; 18(4):860-876. PubMed ID: 34382907
[TBL] [Abstract][Full Text] [Related]
27. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis.
Serrano-Maciá M; Simón J; González-Rellan MJ; Azkargorta M; Goikoetxea-Usandizaga N; Lopitz-Otsoa F; De Urturi DS; Rodríguez-Agudo R; Lachiondo-Ortega S; Mercado-Gomez M; Gutiérrez de Juan V; Bizkarguenaga M; Fernández-Ramos D; Buque X; Baselli GA; Valenti LVC; Iruzubieta P; Crespo J; Villa E; Banales JM; Avila MA; Marin JJG; Aspichueta P; Sutherland J; Barrio R; Mayor U; Elortza F; Xirodimas DP; Nogueiras R; Delgado TC; Martínez-Chantar ML
Mol Metab; 2021 Nov; 53():101275. PubMed ID: 34153521
[TBL] [Abstract][Full Text] [Related]
28. The ménage à trois of autophagy, lipid droplets and liver disease.
Filali-Mouncef Y; Hunter C; Roccio F; Zagkou S; Dupont N; Primard C; Proikas-Cezanne T; Reggiori F
Autophagy; 2022 Jan; 18(1):50-72. PubMed ID: 33794741
[TBL] [Abstract][Full Text] [Related]
29. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
Lee C; Kim J; Jung Y
Cells; 2019 Oct; 8(10):. PubMed ID: 31619023
[TBL] [Abstract][Full Text] [Related]
30. Protein kinase STK25 controls lipid partitioning in hepatocytes and correlates with liver fat content in humans.
Amrutkar M; Kern M; Nuñez-Durán E; Ståhlman M; Cansby E; Chursa U; Stenfeldt E; Borén J; Blüher M; Mahlapuu M
Diabetologia; 2016 Feb; 59(2):341-53. PubMed ID: 26553096
[TBL] [Abstract][Full Text] [Related]
31. Bax inhibitor-1 protects from nonalcoholic steatohepatitis by limiting inositol-requiring enzyme 1 alpha signaling in mice.
Lebeaupin C; Vallée D; Rousseau D; Patouraux S; Bonnafous S; Adam G; Luciano F; Luci C; Anty R; Iannelli A; Marchetti S; Kroemer G; Lacas-Gervais S; Tran A; Gual P; Bailly-Maitre B
Hepatology; 2018 Aug; 68(2):515-532. PubMed ID: 29457838
[TBL] [Abstract][Full Text] [Related]
32. NDR kinase tricornered genetically interacts with Ccm3 and metabolic enzymes in Drosophila melanogaster tracheal development.
Hudson J; Paul S; Veraksa A; Ghabrial A; Harvey KF; Poon C
G3 (Bethesda); 2023 Mar; 13(3):. PubMed ID: 36653023
[TBL] [Abstract][Full Text] [Related]
33. Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans.
Cruces-Sande M; Vila-Bedmar R; Arcones AC; González-Rodríguez Á; Rada P; Gutiérrez-de-Juan V; Vargas-Castrillón J; Iruzubieta P; Sánchez-González C; Formentini L; Crespo J; García-Monzón C; Martínez-Chantar ML; Valverde ÁM; Mayor F; Murga C
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3655-3667. PubMed ID: 30261289
[TBL] [Abstract][Full Text] [Related]
34. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
35. RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.
Afonso MB; Rodrigues PM; Mateus-Pinheiro M; Simão AL; Gaspar MM; Majdi A; Arretxe E; Alonso C; Santos-Laso A; Jimenez-Agüero R; Eizaguirre E; Bujanda L; Pareja MJ; Banales JM; Ratziu V; Gautheron J; Castro RE; Rodrigues CMP
Gut; 2021 Dec; 70(12):2359-2372. PubMed ID: 33361348
[TBL] [Abstract][Full Text] [Related]
36. Pyruvate dehydrogenase kinase 4 mediates lipogenesis and contributes to the pathogenesis of nonalcoholic steatohepatitis.
Zhang M; Zhao Y; Li Z; Wang C
Biochem Biophys Res Commun; 2018 Jan; 495(1):582-586. PubMed ID: 29128353
[TBL] [Abstract][Full Text] [Related]
37. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
Di Ciaula A; Passarella S; Shanmugam H; Noviello M; Bonfrate L; Wang DQ; Portincasa P
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065331
[TBL] [Abstract][Full Text] [Related]
38. Hepatocyte nuclear factor 4α in the pathogenesis of non-alcoholic fatty liver disease.
Pan X; Zhang Y
Chin Med J (Engl); 2022 May; 135(10):1172-1181. PubMed ID: 35191422
[TBL] [Abstract][Full Text] [Related]
39. Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.
Govaere O; Petersen SK; Martinez-Lopez N; Wouters J; Van Haele M; Mancina RM; Jamialahmadi O; Bilkei-Gorzo O; Lassen PB; Darlay R; Peltier J; Palmer JM; Younes R; Tiniakos D; Aithal GP; Allison M; Vacca M; Göransson M; Berlinguer-Palmini R; Clark JE; Drinnan MJ; Yki-Järvinen H; Dufour JF; Ekstedt M; Francque S; Petta S; Bugianesi E; Schattenberg JM; Day CP; Cordell HJ; Topal B; Clément K; Romeo S; Ratziu V; Roskams T; Daly AK; Anstee QM; Trost M; Härtlova A
J Hepatol; 2022 May; 76(5):1001-1012. PubMed ID: 34942286
[TBL] [Abstract][Full Text] [Related]
40. Rubicon inhibits autophagy and accelerates hepatocyte apoptosis and lipid accumulation in nonalcoholic fatty liver disease in mice.
Tanaka S; Hikita H; Tatsumi T; Sakamori R; Nozaki Y; Sakane S; Shiode Y; Nakabori T; Saito Y; Hiramatsu N; Tabata K; Kawabata T; Hamasaki M; Eguchi H; Nagano H; Yoshimori T; Takehara T
Hepatology; 2016 Dec; 64(6):1994-2014. PubMed ID: 27637015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
